Drug Discovery, Delivery, & Experimental Therapeutics Research Program

药物发现，交付和实验治疗-项目摘要 药物发现，交付和实验治疗（D3ET）研究计划整合了广泛的 一系列有助于发现和提供新的癌症治疗策略的研究领域， 识别伴随生物标志物，将最有前途的治疗策略转化为临床 以及这些策略在实验治疗试验中的评价。D3ET是围绕三个， 中心高度集成的科学主题：1）发现和提供新的癌症治疗策略; 2） 开发新的癌症治疗策略; 3）评估新的癌症治疗策略， 实验性治疗试验。D3ET有60名成员（33名博士和27名医学博士），包括39名正式成员和21名 准成员。成员反映了一系列的高级和早期阶段的研究人员与20名教授， 副教授13人，助理教授17人。D3ET成员来自25个部门， 儿童慈善机构，位于劳伦斯的堪萨斯大学和位于劳伦斯的堪萨斯大学医学中心。 堪萨斯城，为学科多样性和团队科学提供了丰富的环境。 在本报告所述期间（2015年），39名正式成员中有51%在外部担任主要研究员。 由同行评审的资助。从2012年到2015年，D3ET计划实现了一个强大的和不断增长的癌症- 专注于研究投资组合。2015年，D3ET成员对36个癌症相关的同行评审进行了研究。 代表910万美元校外资金的项目，包括直接从 国家癌症研究所（NCI）。15个NCI资助的赠款占同行评审资金总额的35%。 D3ET主要通过成员成功获得行业资助来支持临床研究 临床试验活动。D3ET计划在发表其研究方面取得了令人印象深刻的进展， 增加方案内和方案间的合作。2012年至2015年，D3ET 成员发表了617篇癌症相关出版物，其中67篇期刊影响因子≥ 8。 在这段时间内，D3ET发表的研究中有29%代表了项目内研究。 23%的项目涉及跨部门合作。与其研究主题相一致， 51%的D3ET出版物包括外部行业、学术界、政府或疾病 慈善合作者Alan Gamis，MD（儿童慈善）和Scott Weir，PharmD，PhD（KUMC）， 在药物发现、开发和实验疗法方面提供免费的科学专业知识， 有良好的指导记录，共同领导D3ET。Steve威廉姆森，医学博士，临床医学总监 试验办公室和D3ET成员，完成代表成人癌症实验的领导团队 治疗学

Drug Discovery, Delivery and Experimental Therapeutics – Project Summary The Drug Discovery, Delivery and Experimental Therapeutics (D3ET) research program integrates a broad range of research areas that contribute to the discovery and delivery of new cancer therapeutic strategies, identification of companion biomarkers, translation of the most promising therapeutic strategies to the clinic and the evaluation of these strategies in experimental therapeutics trials. D3ET is organized around three, central highly-integrated scientific themes: 1) Discover and Deliver New Cancer Therapeutic Strategies; 2) Develop New Cancer Therapeutic Strategies; and 3) Evaluate New Cancer Therapeutic Strategies in Experimental Therapeutics Trials. D3ET has 60 members (33 PhD's and 27 MD's), including 39 full and 21 associate members. Membership reflects a range of senior and early-stage investigators with 20 Professors, 13 Associate Professors and 17 Assistant Professors. D3ET members are drawn from 25 departments across Children's Mercy, The University of Kansas in Lawrence and The University of Kansas Medical Center in Kansas City, providing a rich environment for discipline diversity and team science. During the reporting period (CY15), 51% of the 39 full members serve as principal investigators on externally funded, peer-reviewed grants. From 2012-2015, the D3ET program achieved a strong and growing cancer- focused research portfolio. In 2015, D3ET members conducted research on 36 cancer-relevant, peer-reviewed projects representing $9.1M in extramural funding, including $3.1M in funding obtained directly from the National Cancer Institute (NCI). The 15 NCI funded grants represented 35% of total peer-reviewed funding. D3ET has grown clinical research primarily by members successfully obtaining grants from industry to support clinical trial activities. The D3ET program has made impressive progress in publishing its research, and increasing intra-programmatic and inter-programmatic collaborations. Between 2012 and 2015, D3ET members published 617 cancer-relevant publications, including 67 papers with a journal impact factor of ≥8. Twenty-nine percent of D3ET published research over this time period represented intra-programmatic collaborations and 23% involving inter-programmatic collaborations. Consistent with its research themes and objectives, 51% of D3ET publications included external industry, academia, government or disease philanthropy collaborators. Alan Gamis, MD (Children's Mercy) and Scott Weir, PharmD, PhD (KUMC), who bring complimentary scientific expertise in drug discovery, development and experimental therapeutics and strong track records of mentorship, jointly lead D3ET. Steve Williamson, MD, Medical Director for the Clinical Trials Office and D3ET member, completes the leadership team representing adult cancer experimental therapeutics.